Contact
Please use this form to send email to PR contact of this press release:
Aurealis Therapeutics receives CTA approval for AUP-16 Phase 2 RCT in Diabetic Foot Ulcer patients
TO:
Laurent Décory, COO
Aurealis Therapeutics